Profile data is unavailable for this security.
About the company
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a pipeline of drug candidates to address the needs of patients with immuno-inflammatory diseases. It has a multi-stage portfolio of drug candidates powered by a robust research and development engine. Its KINect drug discovery platform, combined with its preclinical development capabilities, allows it to identify and advance potential product candidates that it may develop independently or in collaboration with third parties. It has two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment is engaged in the provision of laboratory services. Its drug candidates include Bosakitug (ATI-045), ATI-2138 and ATI-052. Its other investigational product candidates include Lepzacitinib (ATI-1777) and Zunsemetinib (ATI-450).
- Revenue in USD (TTM)15.74m
- Net income in USD-141.68m
- Incorporated2012
- Employees64.00
- LocationAclaris Therapeutics Inc701 Lee Road, Suite 103WAYNE 19087United StatesUSA
- Phone+1 (484) 324-7933
- Fax+1 (302) 655-5049
- Websitehttps://www.aclaristx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anavex Life Sciences Corp | 0.00 | -46.38m | 340.42m | 34.00 | -- | 3.48 | -- | -- | -0.5439 | -0.5439 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -38.75 | -33.08 | -43.11 | -36.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.85 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -19.48m | 349.00m | 4.00 | -- | 159.03 | -- | -- | -1.46 | -1.46 | 0.00 | 0.1584 | 0.00 | -- | -- | 0.00 | -404.39 | -49.65 | -543.43 | -51.94 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -77.57 | -- | -- | -- |
| Forte Biosciences Inc | 0.00 | -51.74m | 360.90m | 16.00 | -- | 4.29 | -- | -- | -4.49 | -4.49 | 0.00 | 6.71 | 0.00 | -- | -- | 0.00 | -89.96 | -64.69 | -110.72 | -71.52 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -12.71 | -- | -38.72 | -- |
| Allogene Therapeutics Inc | 0.00 | -212.02m | 366.31m | 226.00 | -- | 1.15 | -- | -- | -0.981 | -0.981 | 0.00 | 1.41 | 0.00 | -- | -- | 0.00 | -41.21 | -31.11 | -43.96 | -33.14 | -- | -- | -- | -1,187.06 | -- | -- | 0.00 | -- | -76.84 | -- | 21.29 | -- | -57.62 | -- |
| Aclaris Therapeutics Inc | 15.74m | -141.68m | 367.29m | 64.00 | -- | 3.06 | -- | 23.33 | -1.38 | -1.38 | 0.136 | 1.11 | 0.088 | -- | 6.27 | 245,968.80 | -79.17 | -48.16 | -90.39 | -55.11 | 3.98 | 40.68 | -900.01 | -483.49 | -- | -- | 0.00 | -- | -40.09 | 34.67 | -49.26 | -- | 86.02 | -- |
| Bicycle Therapeutics PLC (ADR) | 28.34m | -250.66m | 368.34m | 305.00 | -- | 0.595 | -- | 13.00 | -3.62 | -3.62 | 0.4094 | 8.92 | 0.0322 | -- | 0.4525 | 92,914.76 | -28.47 | -26.61 | -30.66 | -29.60 | -- | -- | -884.51 | -587.28 | -- | -- | 0.0015 | -- | 30.76 | 20.65 | 6.44 | -- | -4.50 | -- |
| Adlai Nortye Ltd (ADR) | 0.00 | -42.59m | 374.17m | 123.00 | -- | 47.24 | -- | -- | -1.14 | -1.14 | 0.00 | 0.2147 | 0.00 | -- | -- | 0.00 | -47.40 | -- | -138.41 | -- | -- | -- | -- | -- | -- | -26.36 | 0.8491 | -- | -- | -- | 52.51 | -- | -- | -- |
| Monopar Therapeutics Inc | 0.00 | -19.44m | 380.11m | 16.00 | -- | 2.68 | -- | -- | -3.44 | -3.44 | 0.00 | 21.25 | 0.00 | -- | -- | 0.00 | -25.88 | -52.66 | -26.53 | -59.31 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -85.50 | -- | -- | -- |
| Absci Corp | 2.82m | -114.60m | 380.44m | 156.00 | -- | 1.80 | -- | 135.15 | -0.903 | -0.903 | 0.022 | 1.40 | 0.0117 | -- | 2.25 | 18,044.87 | -47.73 | -37.10 | -54.08 | -41.33 | -- | -- | -4,071.19 | -1,697.47 | -- | -410.97 | 0.0065 | -- | -20.71 | 17.09 | 6.75 | -- | -18.12 | -- |
| NovaBridge Biosciences | 0.00 | -26.33m | 383.92m | 32.00 | -- | 1.48 | -- | -- | -0.3045 | -0.2827 | 0.00 | 2.25 | 0.00 | -- | -- | 0.00 | -10.32 | -26.21 | -10.92 | -30.19 | -- | -- | -- | -389.26 | -- | -- | 0.00 | -- | -100.00 | -- | 39.56 | -- | -51.41 | -- |
| Entrada Therapeutics Inc | 61.52m | -103.46m | 384.87m | 183.00 | -- | 1.13 | -- | 6.26 | -2.50 | -2.50 | 1.47 | 8.91 | 0.1272 | -- | 32.39 | 336,174.90 | -21.39 | -8.44 | -23.70 | -10.02 | -- | -- | -168.16 | -33.36 | -- | -- | 0.00 | -- | 63.38 | -- | 1,081.69 | -- | 38.04 | -- |
| Lineage Cell Therapeutics Inc | 10.82m | -67.66m | 386.95m | 70.00 | -- | 17.56 | -- | 35.78 | -0.2955 | -0.2955 | 0.0469 | 0.0957 | 0.1162 | -- | 40.66 | 154,514.30 | -72.50 | -20.81 | -81.52 | -24.54 | 97.84 | 90.99 | -624.16 | -331.61 | -- | -- | 0.004 | -- | 6.19 | 22.00 | 13.39 | -- | 5.13 | -- |
| Northwest Biotherapeutics Inc | 937.00k | -91.22m | 390.81m | 25.00 | -- | -- | -- | 417.08 | -0.0655 | -0.0655 | 0.0007 | -0.0627 | 0.0313 | -- | -- | 37,480.00 | -299.59 | -398.92 | -- | -- | -- | -- | -9,580.90 | -8,255.92 | -- | -6.69 | -- | -- | -28.47 | -10.53 | -32.34 | -- | 23.01 | -- |
| DiaMedica Therapeutics Inc | 0.00 | -31.93m | 392.66m | 27.00 | -- | 7.61 | -- | -- | -0.7173 | -0.7173 | 0.00 | 0.9913 | 0.00 | -- | -- | 0.00 | -58.27 | -43.91 | -63.85 | -46.83 | -- | -- | -- | -- | -- | -- | 0.0003 | -- | -- | -- | -26.12 | -- | 65.72 | -- |
Data as of Feb 06 2026. Currency figures normalised to Aclaris Therapeutics Inc's reporting currency: US Dollar USD
44.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BML Capital Management LLCas of 30 Sep 2025 | 14.25m | 13.15% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 5.84m | 5.39% |
| Adage Capital Management LPas of 30 Sep 2025 | 5.28m | 4.87% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 5.14m | 4.74% |
| Rock Springs Capital Management LPas of 30 Sep 2025 | 4.61m | 4.25% |
| Morgan Stanley & Co. LLCas of 30 Sep 2025 | 4.06m | 3.75% |
| Geode Capital Management LLCas of 30 Sep 2025 | 2.39m | 2.21% |
| D. E. Shaw & Co. LPas of 30 Sep 2025 | 2.37m | 2.19% |
| Acadian Asset Management LLCas of 30 Sep 2025 | 2.33m | 2.15% |
| Marshall Wace LLPas of 30 Sep 2025 | 1.72m | 1.59% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
